Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences
Published
STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2
Full Article